Bausch & Lomb is the largest private sector employer in the southeast.

Eye-care company Bausch & Lomb is to create 50 new jobs over the next 18 months as part of a €41 million investment at its Waterford facility.The (...)

Valeant had said it was willing to pay at least $200 a share and has the backing of Allergan’s largest shareholder -- activist investor Bill Ackman’s (pictured) Pershing Square Capital Management LP. ( Photograph: Scott Eells/Bloomberg)

Actavis has agreed to pay about $66 billion (€52.6bn) for Allergan, after the maker of Botox turned to the drugmaker to repel a hostile advance from V(...)

A doctor injects a patient with Allergan’s Botox. Photographer: Patrick T. Fallon/Bloomberg

Botox maker Allergan, which is fending off an acquisition by Valeant Pharmaceuticals, said today that it had been approached by another party regardi(...)

Botox producer Allergan  is resisting Valeant’s hostile offer. Photograph: Shannon Stapleton/Reuters

Valeant Pharmaceuticals said in a letter yesterday to Allergan’s board of directors that it was prepared to raise its offer to at least $200 per share(...)

 Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire. Photo: Eric Luke/The Irish Times

Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire as an alternative to (...)

The purchase of Auxilium Pharmaceuticals will add to Endo’s offerings of branded pharmaceuticals.

Endo International has agreed to buy Auxilium Pharmaceuticals for $2.6 billion to gain testosterone products. Dublin-headquartered Endo will pay $33.(...)

The head offices of Valeant Pharmaceuticals International in Quebec. The ISS report comes as Allergan’s largest shareholder, hedge fund Pershing Square Capital Management, is urging the Botox maker to sell itself to Valeant. Photograph: Reuters/Christinne Muschi

Prominent investor shareholder advisory firm ISS called on Allergan to give its shareholders a chance to vote on any large, buyout-blocking acquisitio(...)

Hasbro lost 3.3 per cent to $51.46. The toys and game maker reported second-quarter revenue that fell short of estimates. Photograph: Reuters

Shares fell across the globe as fighting erupted in eastern Ukraine, the first major eruption of violence there since a Malaysian airliner was shot do(...)

Allergan chief executive David Pyott. Allergan said the cost reductions, which are part of its efforts to convince investors that it is a better value as a stand-alone company, would help it deliver annual earnings growth of more than 20 per cent between 2014 and 2019.

Botox maker Allergan, which is fighting off a hostile bid from Valeant Pharmaceuticals, today announced 1,500 jobs cuts as part of a $475 million rest(...)

The Food and Drug Administration approved Allergan’s Ozurdex, a drug for diabetic macular edema, which can cause vision loss and eventual blindness in people with diabetes, according to a regulatory filing today.

Allergan, the drugmaker resisting a takeover by Valeant Pharmaceuticals International , won US approval for a treatment of vision loss in diabetics a(...)